Fabrice Paublant Presents Orixha at LSI Europe '23

Transcription

Fabrice Paublant  0:05  
Good afternoon, ladies and gentlemen. Fabrice Paublant from Orixha. And I'm afraid I have bad news for you today. It's about 3pm. So we most of us are reaching a peak in postprandial fatigue. So in order to fight this urge for siesta, I offer, we talked about something completely different today. Liquid ventilation. Liquid ventilation means breathing a liquid. But that's James Cameron stuff, right, but science fiction what it was. But in 2044, it will become a clinical reality. With VentiCool, our first product based on our proprietary local life technology, and local lifestyles from lung conservative liquid ventilation. With learn to live by exclusively ventilating a patient with a breathable liquid, you provide two major and essential life support functions for critical care. The first function is precise. And in rapid terminal control of the patient, the breathable liquid is a terminal vector. And therefore, we can use the lungs as a heat exchanger to very rapidly induced hypothermia. And that's what ventricle is doing for cardiac arrest patients. The second life support function is lung protective ventilatory respiratory support. The breathable liquid acts as a mechanical barrier for the alveoli against the local inflammation in the lungs. And therefore with ventibreathe our second product, we can provide physiological, non inflammatory respiratory support to ARDS patients, for instance. Over the past 10 years, with performing exhaustive proof of concept on the Lincoln life technology on more than 25 in vivo models, including human sized pigs, and non human primates to validate the safety, the performance, as well as neuro protection and cargo protection, leading to survival gains in those animal relevant animal models. But now it's time to come to the clinic and to save lives. And that's what we will do with Venticool. So how does it work? Well, you have a comatose patient intubated, on the on the right and on the left, or right on your left and on my right. And on the other side, you have a liquid ventilator ventricle liquidator that performs three key functions. First, it will ventilate the patient with about one liter of reasonable liquid every 10 seconds. At the same time, it will remove the liquid which is in the device, it will this liquid it will remove the carbon dioxide and real oxygenated. And third of all, it will precisely control the temperature of this liquid to induce a rapid hypothermia and protect those patients from the cardiac arrest syndrome. Venticool addresses a major unmet medical need post cardiac syndrome also called as PCs. As you can see on the cardiac arrest survival chain, less than one out of 10 cardiac arrest patients when the cardiac arrest habits out of the house out of hospital survives in the end. And that's because two thirds of the patients, the patients who have been initially resuscitated two sets of stations die in the hospital from PCS. That's 100,000 150,000 deaths everywhere every year sorry, in Europe and US from PCS. And we will tackle that with the ventricle system that you see here. The goal is to improve the overall survival in good normal conditions, good neurological conditions for those initially resisted patience for and we want to save more than 50% of those patient instead of 30 to 35% as currently is done by current solutions. It is well known from preclinical data and it's corroborated by real life clinical clinical data. That cooling speed is the dose effect in PCs. The faster you reach 33 degrees, the more potent you are and the more gain you have on survival than to cool is the only solution to hit the two hours therapeutic window to protect efficiently the patient from the cytokine storm that arises in PCs. The other solutions take more than four hours and therefore have very limited efficacy on the cytokine storm. Here you see what is both a competitive competition and a partnering flight. Actually, except for the XO solution, the thermal guard and the vascular system which is in the middle, and which accounts for less than 3% of the total procedures, or the main players like BD and Stryker, who develop and commercialize Excel cooling systems, and welcoming the arrival of VentiCool on the market for two good reasons. First, Venticool, we take care exclusively of the induction phase of therapeutic hypothermia. So we still need this, there are solutions there are external cooling solutions for the maintenance and the warming phase. And second of all, with the added efficacy, and the increase in the significant effect size on PCS, from the ventricular therapies induction, the whole field will be boosted by finally having an efficacious solution to treat those patients, and the ventricle tide will lift all the boats. So what happens once we validate the superiority of ventricle, and we have ventricle included in the cardiac arrest guidelines. As you can see, out of the 700,000 patients every year who suffer from out of hospital cardiac arrest Europe in the US, to 20,000 of them are resuscitated. And if we take into account and to our therapeutic window to act on them and bring benefits, we estimate 140,000 patients who could benefit from ventricular for a year. That's with a revenue model of $10,000 per patient, by 2030, Orixha, will be addressing a $1.2 billion dollar market in Europe and the US and we'll be saving close to 20,000 additional lives every year. This year, we achieved the the r&d completion of the Venticool solution. And now we're entering the clinical and regulatory validation, which will take us to commercialization in 2027. Tickle validation will start early next year in hospital Kosha in Paris, and in Basil to leading Kaliakra centers will be followed by a pivotal randomized clinical trial on both sides of the Atlantic, and the post market priority study. This ambitious plan is powered by a strong ecosystem with the center of the ecosystem, a management team, a core team, with experienced managers, and hardware and software development experience in quality and regulatory as our medical and marketing affairs. We also have the chance to have first class industrial partners are on board. You can see their logos here on the slide. And we have the support of the key KOLs in the field in cardiac arrest on both sides of the Atlantic people such as professor, and I got you in Paris, In Brussels, and Graham Nicole in Seattle. So we're currently working on two fundraising rounds. The first one that we will close in the coming month, a convertible bond bound round, led by the EIB that will cover the next two years of financing for the clinic, first initial clinical validation of VentiCool and then looking forward to a Series A round of 15 to 20 billion euros in 2025 to cover the final trick of ideation and the early commercial commercialization phase in Europe for Venticool. So with that being said, let's meet in Barcelona to my clinical to make liquid ventilation a clinical reality together. Thank you for your attention.